X J Qiao1, B M Ellingson1, H J Kim1, D J J Wang2, N Salamon1, M Linetsky1, A R Sepahdari1, B Jiang3, J J Tian1, S R Esswein1, T F Cloughesy2, A Lai2, L Nghiemphu2, W B Pope4. 1. From the Departments of Radiological Sciences (X.J.Q., B.M.E., H.J.K., N.S., M.L., A.R.S., J.J.T., S.R.E., W.B.P.). 2. Neurology (D.J.J.W., T.F.C., A.L., L.N.), David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California. 3. Department of Radiology (B.J.), Second Affiliated Hospital, Zhejiang University, Hangzhou, China. 4. From the Departments of Radiological Sciences (X.J.Q., B.M.E., H.J.K., N.S., M.L., A.R.S., J.J.T., S.R.E., W.B.P.) wpope@mednet.ucla.edu.
Abstract
BACKGROUND AND PURPOSE: Glioblastoma is a common primary brain tumor with a poor but variable prognosis. Our aim was to investigate the feasibility of MR perfusion imaging by using arterial spin-labeling for determining the prognosis of patients with glioblastoma. MATERIALS AND METHODS: Pseudocontinuous arterial spin-labeling with 3D background-suppressed gradient and spin-echo was acquired before surgery on 53 patients subsequently diagnosed with glioblastoma. The calculated CBF color maps were visually evaluated by 3 independent readers blinded to patient history. Pathologic and survival data were correlated with CBF map findings. Arterial spin-labeling values in tumor tissue were also quantified by using manual fixed-size ROIs. RESULTS: Two perfusion patterns were characterized by visual evaluation of CBF maps on the basis of either the presence (pattern 1) or absence (pattern 2) of substantial hyperperfused tumor tissue. Evaluation of the perfusion patterns was highly concordant among the 3 readers (κ = 0.898, P < .001). Pattern 1 (versus pattern 2) was associated with significantly shorter progression-free survival by Kaplan-Meier analysis (median progression-free survival of 182 days versus 485 days, P < .01) and trended with shorter overall survival (P = .079). There was a significant association between pattern 1 and epidermal growth factor receptor variant III expression (P < .01). CONCLUSIONS: Qualitative evaluation of arterial spin-labeling CBF maps can be used to stratify survival and predict epidermal growth factor receptor variant III expression in patients with glioblastoma.
BACKGROUND AND PURPOSE:Glioblastoma is a common primary brain tumor with a poor but variable prognosis. Our aim was to investigate the feasibility of MR perfusion imaging by using arterial spin-labeling for determining the prognosis of patients with glioblastoma. MATERIALS AND METHODS: Pseudocontinuous arterial spin-labeling with 3D background-suppressed gradient and spin-echo was acquired before surgery on 53 patients subsequently diagnosed with glioblastoma. The calculated CBF color maps were visually evaluated by 3 independent readers blinded to patient history. Pathologic and survival data were correlated with CBF map findings. Arterial spin-labeling values in tumor tissue were also quantified by using manual fixed-size ROIs. RESULTS: Two perfusion patterns were characterized by visual evaluation of CBF maps on the basis of either the presence (pattern 1) or absence (pattern 2) of substantial hyperperfused tumor tissue. Evaluation of the perfusion patterns was highly concordant among the 3 readers (κ = 0.898, P < .001). Pattern 1 (versus pattern 2) was associated with significantly shorter progression-free survival by Kaplan-Meier analysis (median progression-free survival of 182 days versus 485 days, P < .01) and trended with shorter overall survival (P = .079). There was a significant association between pattern 1 and epidermal growth factor receptor variant III expression (P < .01). CONCLUSIONS: Qualitative evaluation of arterial spin-labeling CBF maps can be used to stratify survival and predict epidermal growth factor receptor variant III expression in patients with glioblastoma.
Authors: Erwin G Van Meir; Costas G Hadjipanayis; Andrew D Norden; Hui-Kuo Shu; Patrick Y Wen; Jeffrey J Olson Journal: CA Cancer J Clin Date: 2010 May-Jun Impact factor: 508.702
Authors: Elana S Tykocinski; Ryan A Grant; Gurpreet S Kapoor; Jaroslaw Krejza; Leif-Erik Bohman; Timothy A Gocke; Sanjeev Chawla; Casey H Halpern; Joanna Lopinto; Elias R Melhem; Donald M O'Rourke Journal: Neuro Oncol Date: 2012-04-04 Impact factor: 12.300
Authors: Danny J J Wang; Jeffry R Alger; Joe X Qiao; Qing Hao; Samuel Hou; Rana Fiaz; Matthias Gunther; Whitney B Pope; Jeffrey L Saver; Noriko Salamon; David S Liebeskind Journal: Stroke Date: 2012-02-09 Impact factor: 7.914
Authors: Bob L Hou; Sijin Wen; Gennadiy A Katsevman; Hui Liu; Ogaga Urhie; Ryan C Turner; Jeffrey Carpenter; Sanjay Bhatia Journal: World Neurosurg Date: 2018-12-27 Impact factor: 2.104